Everett Harris & Co. CA Sells 8,235 Shares of Organon & Co. (NYSE:OGN)

Everett Harris & Co. CA lowered its position in Organon & Co. (NYSE:OGN) by 17.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,297 shares of the company’s stock after selling 8,235 shares during the period. Everett Harris & Co. CA’s holdings in Organon & Co. were worth $771,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in OGN. Teachers Retirement System of The State of Kentucky increased its holdings in shares of Organon & Co. by 250.3% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 80,128 shares of the company’s stock worth $1,155,000 after acquiring an additional 57,255 shares in the last quarter. GAMMA Investing LLC increased its stake in Organon & Co. by 29.5% during the 1st quarter. GAMMA Investing LLC now owns 3,387 shares of the company’s stock worth $64,000 after purchasing an additional 772 shares in the last quarter. Wedmont Private Capital acquired a new stake in Organon & Co. during the 1st quarter worth approximately $214,000. Douglas Lane & Associates LLC lifted its stake in Organon & Co. by 35.3% in the first quarter. Douglas Lane & Associates LLC now owns 488,304 shares of the company’s stock valued at $9,180,000 after buying an additional 127,529 shares in the last quarter. Finally, Ballentine Partners LLC boosted its holdings in shares of Organon & Co. by 11.9% in the first quarter. Ballentine Partners LLC now owns 18,553 shares of the company’s stock valued at $349,000 after buying an additional 1,969 shares during the period. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

NYSE OGN opened at $17.61 on Friday. The firm’s 50 day moving average is $19.98 and its 200-day moving average is $20.14. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05. The company has a market capitalization of $4.53 billion, a PE ratio of 4.53, a price-to-earnings-growth ratio of 0.79 and a beta of 0.84. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $23.10.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.04. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The firm had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.61 billion. During the same period in the previous year, the business earned $1.31 EPS. The company’s revenue was down .1% compared to the same quarter last year. Equities research analysts anticipate that Organon & Co. will post 4.15 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 12th. Investors of record on Friday, August 16th were issued a dividend of $0.28 per share. The ex-dividend date was Friday, August 16th. This represents a $1.12 annualized dividend and a yield of 6.36%. Organon & Co.’s payout ratio is presently 28.79%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their price target for the company from $18.00 to $20.00 in a report on Friday, September 6th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.